Otsuka, PhoreMost Team Up for Drug Discovery
Otsuka will use PhoreMost’s phenotypic screening platform to identify new targets for drug development, with a focus on gene therapy.
On January 21, 2020, Otsuka Pharmaceutical and PhoreMost, a Cambridge, UK-based biopharmaceutical company, entered into a multi-project drug discovery collaboration that will pursue both small molecule therapeutics as well as gene therapy applications.
PhoreMost will contribute its in-house expertise and phenotypic screening platform, Siteseeker, to evaluate disease-relevant pathways nominated by Otsuka, which will further characterize and validate novel targets that have been identified. The partners will initially focus on gene therapy applications, according to a company press release.
PhoreMost’s platform, which is based on Proteini, a proprietary protein interference technology, exploits protein shape diversity to find functionally active peptides. This approach can significantly enhance the power of phenotypic screening and translation into therapeutic modalities, company executives claim. PhoreMost uses Siteseeker to probe the entire proteome in a live cell environment to identify novel druggable targets linked to any chosen disease. This enables the systematic discovery of the functionally active peptides that are directly linked to useful therapeutic applications, according to PhoreMost.
Source: PhoreMost
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
